We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu
IMPORTANT: Due to the lapse in government funding, the information on this web site may not be up to date, transactions submitted via the web site may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers (OMEGA3CHOCO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01391624
Recruitment Status : Completed
First Posted : July 12, 2011
Last Update Posted : July 12, 2011
Information provided by:

Study Description
Brief Summary:

The purpose of this study is to determine whether essential polyunsaturated acids (omega 3) are capable of reducing chocolate craving symptoms in healthy patients.

Our hypothesis is that the omega 3 fatty acids have properties which stabilize and normalize neuronal functioning in many conditions, including chocolate craving.

Condition or disease Intervention/treatment Phase
Addictive Behavior Abstinence Syndrome Drug: Flaxseed oil Drug: Paraffin + # 2 dye Phase 2 Phase 3

Detailed Description:

Polyunsaturated fatty acids (of the omega 3 subtype) are fundamental in human diet, as they are components of cellular membranes, guaranteeing their fluidity and their functions of separating intracellular and extracellular means and transporting several substances to and from cellular microenvironment.

Modern theories profess that lack of omega 3 fatty acids in western diets may be the cause of several deletery changes in neuronal physiology, which may cause or make worse several pathological conditions, such as depression, mood instability, and drug craving. The role of serotonin as the main lacking component in the conditions is well documented, and it is thought that omega 3 is important in the synthesis, transportation, and ultimately the activity of this neurotransmitter.

Out theory states that supplementation with these acids can restore normal neuron balance, improving the condition of chocolate craving patients.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Study on the Possible Effects of Diet Supplementation With Essential Fatty Acids in Chocolate Craving Volunteers
Study Start Date : August 2010
Primary Completion Date : January 2011
Study Completion Date : January 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Minerals
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: Omega 3
The group was treated with omega 3 fatty acids for 2 months.
Drug: Flaxseed oil
3 g (3 capsules/day) of flax oil for a period of 8 weeks
Other Names:
  • DHA
  • EPA
  • Essential fatty acids
Placebo Comparator: Placebo
The group received paraffin with dye in order to mimic the visual aspects of omega 3 fatty acid capsules.
Drug: Paraffin + # 2 dye
3 capsules of mineral oil (ineffective) for 8 weeks.
Other Name: Mineral oil

Outcome Measures

Primary Outcome Measures :
  1. Changes in the MBES score (used to quantify chocolate compulsion) from baseline. [ Time Frame: 2 months after enrollment ]
    The MBES is an objective scale used to quantify compulsion and classify chocolate cravers in three categories: low, moderate and severe cravers. The scale was applied to all volunteers at baseline and 2 months after enrollment in the study, and comparisons were made to establish if there was efficacy of treatment with omega 3 when compared with placebo (with decreased grades in the MBES scale).

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Clinical diagnosis of chocolate compulsion or craving, ECAP score > 12.

Exclusion Criteria:

  • Psychiatric disease of any sort (by the DSM IV criteria, Use of psychoactive drugs of any sort, BMI > 25 (kg/m2).
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01391624

Universidade Federal de São Paulo (Federal University of São Paulo); Departamento de Psicobiologia (Department of Psychobiology)
São Paulo, Brazil, 04023-062
Sponsors and Collaborators
Federal University of São Paulo
Associação Fundo de Incentivo à Pesquisa
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Study Chair: Pedro L Prior, Student Student
More Information

Responsible Party: José Carlos Fernandes Galduróz, MD, PhD, Adjunct Professor in the Department of Psychobiology of the Federal University of São Paulo
ClinicalTrials.gov Identifier: NCT01391624     History of Changes
Other Study ID Numbers: Omega3-chocolate-001
First Posted: July 12, 2011    Key Record Dates
Last Update Posted: July 12, 2011
Last Verified: July 2011

Keywords provided by Federal University of São Paulo:

Additional relevant MeSH terms:
Behavior, Addictive
Compulsive Behavior
Impulsive Behavior
Mineral Oil
Dermatologic Agents